Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Cold-fx. (Kevin Van Paassen/Kevin Van Paassen/The Globe and Mail)
Cold-fx. (Kevin Van Paassen/Kevin Van Paassen/The Globe and Mail)

Valeant takes control of Afexa, extends bid Add to ...

Valeant Pharmaceuticals International Inc. says it has acquired nearly 81 million shares of Cold-FX maker Afexa Life Sciences Inc., or nearly 74 per cent of the Edmonton drug maker, under a friendly takeover offer.

Valeant said Tuesday it will extend its bid to Oct. 27 to acquire the rest of the shares and privatize Afexa.

The Toronto-area drug maker, formerly known as Biovail, wants to buy Afexa to expand the company's flu treatment sales globally.

In the know

Most popular videos »

Highlights

More from The Globe and Mail

Most popular